UBS Group’s Relmada Therapeutics RLMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $108K | Buy |
180,471
+35,682
| +25% | +$21.4K | ﹤0.01% | 5909 |
|
|
2025
Q1 | $39.1K | Sell |
144,789
-70,351
| -33% | -$19K | ﹤0.01% | 6473 |
|
|
2024
Q4 | $112K | Buy |
215,140
+88,755
| +70% | +$46.2K | ﹤0.01% | 5586 |
|
|
2024
Q3 | $409K | Sell |
126,385
-2,415
| -2% | -$7.83K | ﹤0.01% | 4228 |
|
|
2024
Q2 | $386K | Sell |
128,800
-485
| -0.4% | -$1.46K | ﹤0.01% | 4107 |
|
|
2024
Q1 | $601K | Buy |
129,285
+3,555
| +3% | +$16.5K | ﹤0.01% | 3951 |
|
|
2023
Q4 | $521K | Buy |
125,730
+42
| +0% | +$174 | ﹤0.01% | 3940 |
|
|
2023
Q3 | $377K | Buy |
125,688
+26,700
| +27% | +$80.1K | ﹤0.01% | 3807 |
|
|
2023
Q2 | $244K | Buy |
98,988
+97,410
| +6,173% | +$240K | ﹤0.01% | 4331 |
|
|
2023
Q1 | $3.57K | Sell |
1,578
-4,335
| -73% | -$9.8K | ﹤0.01% | 7202 |
|
|
2022
Q4 | $20.6K | Sell |
5,913
-171
| -3% | -$597 | ﹤0.01% | 6443 |
|
|
2022
Q3 | $225K | Buy |
6,084
+4,756
| +358% | +$176K | ﹤0.01% | 3970 |
|
|
2022
Q2 | $25K | Hold |
1,328
| – | – | ﹤0.01% | 5580 |
|
|
2022
Q1 | $36K | Sell |
1,328
-1,869
| -58% | -$50.7K | ﹤0.01% | 5795 |
|
|
2021
Q4 | $72K | Sell |
3,197
-1,522
| -32% | -$34.3K | ﹤0.01% | 5510 |
|
|
2021
Q3 | $124K | Buy |
4,719
+98
| +2% | +$2.58K | ﹤0.01% | 4606 |
|
|
2021
Q2 | $148K | Sell |
4,621
-1,925
| -29% | -$61.7K | ﹤0.01% | 4553 |
|
|
2021
Q1 | $230K | Sell |
6,546
-873
| -12% | -$30.7K | ﹤0.01% | 4418 |
|
|
2020
Q4 | $238K | Buy |
7,419
+1,805
| +32% | +$57.9K | ﹤0.01% | 4175 |
|
|
2020
Q3 | $211K | Sell |
5,614
-2,747
| -33% | -$103K | ﹤0.01% | 3960 |
|
|
2020
Q2 | $374K | Buy |
8,361
+5,318
| +175% | +$238K | ﹤0.01% | 3594 |
|
|
2020
Q1 | $104K | Sell |
3,043
-1,214
| -29% | -$41.5K | ﹤0.01% | 4403 |
|
|
2019
Q4 | $166K | Buy |
+4,257
| New | +$166K | ﹤0.01% | 4709 |
|